Related by context. All words. (Click for frequent words.) 72 SYMMETRY SM trial 71 IMPACT DCM 70 Phase Ib IIa 69 By JENNIFER LEARN 69 Phase Ib II 69 Randomized Phase II 69 BRIM3 69 Bayer HealthCare Onyx Pharmaceuticals 68 Prostate AdenoCarcinoma Treatment 68 multicenter Phase II 68 rALLy clinical trial 68 Oral Fingolimod 68 INSPIRE Trial Phase III 67 Combination REOLYSIN R 67 number NCT# ClinicalTrials.gov 67 recombinant PSMA vaccine 67 pralatrexate injection folate analogue 67 kidney urologic 67 XL# SAR# 67 CYT# potent vascular disrupting 67 tramiprosate Alzhemed TM 67 Oral Calcitonin 67 Hsp# Inhibitor 66 Phase #b/#a clinical 66 Telik logo TELINTRA 66 MKC# MT 66 evaluating satraplatin plus 66 refractory chronic lymphocytic 66 Heterozygous Familial Hypercholesterolemia 66 Phase 2b Clinical Trial 66 memantine HCl 66 pharmacogenomic translational research 66 sarcoma melanoma 66 Aeolus Pharmaceuticals Announces 66 recurrent metastatic ovarian cancer 66 Telik Announces 66 Recurrent Glioblastoma 66 Completes Patient Enrollment 66 Glufosfamide 65 R lenalidomide 65 ThermoDox ® clinical 65 Synta Announces 65 Humanized Anti 65 alvespimycin 65 BRIM2 65 Phase 1b clinical trials 65 EXPLORE Xa 65 JAK2 Inhibitor 65 VEGFR2 inhibitor 65 Newly Diagnosed Multiple Myeloma 65 novel VDA molecule 65 Phase IIb III 65 ADVANCE ILLUMINATE 65 lintuzumab SGN 65 Phase 2b Trial 65 Crofelemer budesonide foam 65 chronic eosinophilic leukemia 65 evaluating mipomersen 65 Motesanib 65 MCSP respectively 65 EMPOWER ™ 65 IMPACT IMmunotherapy 65 Initiates Phase II 65 Begins Dosing 65 Randomized Double blind 65 sapacitabine CYC# 65 oral ghrelin agonist 65 IIa Clinical Trial 65 recurrent glioblastoma multiforme 65 Phase Ib clinical 64 LHRH receptor positive 64 demonstrated antitumor activity 64 Syncria albiglutide 64 orally administered synthetic retinoid 64 phase IIb study 64 MKC# MKC# PP 64 develop HBV reactivation 64 Kit CD# positive 64 Hormone Refractory Prostate Cancer 64 dimebon latrepirdine 64 IIa clinical trial 64 catheter occlusion 64 systemic Phase 1b 64 BCIRG 64 Callisto initiated 64 SUTENT ® 64 unique alkylating agent 64 interferon alpha IFN 64 Mg Usa 64 LymphoStat B belimumab 64 hypereosinophilic syndrome 64 Severe Sepsis 64 phase IIb clinical 64 Vaccine Immunology 64 Prednisone Against Refractory 64 metastatic castration resistant 64 Romidepsin 64 R# #mg BID 64 Teriflunomide 64 #/#/# Cytokinetics Incorporated 64 Empatic ™ 64 evaluating Prochymal 64 Personalized Immunotherapy 64 3 registrational trial 64 CALGB # [002] 64 oral picoplatin 64 brand ciclesonide HFA 64 recurrent malignant glioma 64 MYTHOS trial 64 evaluating picoplatin 64 papillary renal cell carcinoma 64 Dementia Related Psychosis 64 deCODE ProstateCancer TM 64 Second Pivotal Phase 64 Hedgehog Pathway Inhibitor 64 Initiates Enrollment 64 IMPDH inhibitor 64 Clinical Trial Results 64 evaluating tivozanib 64 EXECUTIVE SUMMARY II 64 HCV Protease Inhibitor 64 CAMMS# 64 CHAMPION PCI 64 Ribavirin causes 64 XL# anticancer compounds 64 TransVax 64 GVAX ® 64 4SC AG ISIN DE# 64 HCV NS5B polymerase 64 AAG geldanamycin analog 64 Safinamide 64 FOLFOX6 chemotherapy regimen 63 ICON7 63 psoriatic arthritis PsA 63 evaluating Actimmune 63 cytidine nucleoside analog 63 Achieves Primary Endpoint 63 HDAC Inhibitor 63 ATRA IV 63 Arno Therapeutics 63 bone marrow reticulin deposition 63 Annamycin 63 NicVAX TM 63 #rd Annual CTRC 63 registrational Phase 63 Budesonide foam crofelemer 63 PF # [002] 63 Multicenter Phase 63 ACAPODENE 63 Sapacitabine 63 essential thrombocythemia ET 63 Randomized Clinical Trials 63 antiretroviral naïve 63 See CLINICAL PHARMACOLOGY 63 aggressive systemic mastocytosis 63 Relapsed Refractory 63 Initiate Phase III 63 Initiated Phase 63 Biogen Genentech 63 Ocrelizumab 63 Multicenter Randomized 63 Pharmacokinetics PK 63 LymphoStat B TM 63 relapsed MM 63 YOUR LOCAL ANIMAL SHELTER 63 Edge STudy 63 multicenter randomized controlled 63 SNT-MC#/idebenone 63 Meets Primary Endpoint 63 Renal Impairment 63 rash pruritus nausea 63 AVOREN 63 TransVax ™ 63 FDA Approves Novel 63 fosbretabulin 63 Pivotal Phase III 63 PROTECT AF 63 IIa clinical 63 Shows Promise Against 63 Subgroup analysis 63 Afatinib 63 subcutaneous PRO 63 II Clinical Trial 63 Demonstrates Sustained 63 PANVAC VF 63 including eniluracil ADH 63 Prolongs Survival 63 Cancer Incidence Mortality 63 PORxin TM platforms 63 RhuDex 63 novel orally inhaled 63 ORAL Solo 63 Initiates Clinical Trial 63 hypoxia activated prodrug 63 anti VEGF aptamer 63 ongoing Phase 1b 63 Tyrosine Kinase Inhibitor 63 JAK#/JAK# inhibitor CYT# 63 FOLOTYN ® 63 ELACYT 63 Nasdaq PGNX today 63 antiangiogenesis therapies 63 pharmacokinetic PK study 63 receiving chemoradiation therapy 63 CLARITY study 63 Evidence Therapeutic 63 hGH CTP Phase 63 Investigational Treatment 63 PCI ExTRACT TIMI 63 CARE HF 63 confirmatory clinical 63 DOI #.#/hep.# 63 Dose Limiting Toxicity DLT 63 Omacetaxine 63 Study Evaluating 63 R sorafenib tablets 63 Dacogen injection 63 Plicera 63 PLX STROKE targeting 63 Randomized Double Blind 63 solid tumors ZYBRESTAT 62 Medidur TM FA 62 dependent kinase inhibitor 62 Enzastaurin 62 onset idiopathic hypogonadism 62 commercialize CorMedix drug 62 systemic anaplastic large 62 Provectus Pharmaceuticals specializes 62 Multiple Ascending Dose 62 Demonstrate Significant 62 Pirfenidone 62 Demonstrates Positive 62 Testosterone MDTS ® 62 oral nucleoside analogue 62 Randomized Phase 62 Teva Provides Update 62 Vicriviroc 62 Relapsed Multiple Myeloma 62 indolent follicular non 62 Proellex TM 62 Namenda Memantine HCl 62 Dose Escalation 62 evaluating satraplatin 62 Cloretazine ® 62 HCV RESPOND 2 62 Phase III Pivotal 62 Prodarsan R 62 compound INCB# 62 Placebo Controlled 62 Treatment Naive Patients 62 Pegloticase 62 Kamada AAT 62 lead Aganocide compound 62 developed preclinically 62 Oral Laquinimod 62 samalizumab 62 Services #:#-#,# Abstract 62 phase IIa clinical 62 GVAX AML 62 RhuDex R 62 R Saizen R 62 budesonide foam 62 particularly SANCTURA XR 62 Phase III ADT 62 SUCCEED trial 62 riociguat 62 Novel Oral 62 EDEMA3 trial 62 next generation URAT1 62 Aflibercept 62 intravenous belinostat 62 Prospective Randomized 62 ARRY # 62 Mg Uk 62 galiximab 62 Gentium Announces 62 blinded randomized placebo controlled 62 SCHIZOPHRENIA DISORDERS SUPPORT GROUP 62 opioid naive 62 Immunotherapeutic 62 non nucleoside inhibitor 62 ENESTnd 62 dose escalation clinical 62 Hedgehog Pathway 62 BY WILLA J. 62 metastatic pancreatic 62 STRIDE PD 62 myelodysplastic myeloproliferative diseases 62 telomerase therapeutic 62 D aspartate NMDA receptor 62 patients coinfected 62 undergoing elective percutaneous 62 DEB# 62 CD# CEA 62 personalized cellular immunotherapy 62 gastrointestinal mucositis 62 Long Term Efficacy 62 humanized therapeutic 62 myocardial infarction ventricular fibrillation 62 Sangamo BioSciences Announces 62 Chronic Myeloid Leukemia 62 resistant hormone refractory 62 PROSTVAC VF 62 SPRYCEL ® 62 placebo controlled multicenter 62 acetonide FA 62 novel therapeutic antibodies 62 IT HARD TO 62 Pharmacyclics Announces 62 Tarvacin Anti Cancer 62 Clinical Trials Update 62 reduce serum phosphate 62 hyperphenylalaninemia HPA due 62 Phase Ib Clinical Trial 62 Presents Positive 62 Neuroendocrine Tumors 62 Diabetic Foot Ulcer 62 SPEAR Study 62 #:#-#,# CrossRef Medline [001] 62 AKT inhibitor 62 CG# oncolytic virus 62 myelofibrosis polycythemia vera 62 trastuzumab DM1 T DM1 62 triggers apoptosis programmed 62 Nymox Announces 62 comparing alemtuzumab 62 Successfully Completes Phase 62 Phase III multicenter 62 basal bolus regimen 62 Acute Myeloid Leukemia AML 62 Treatment Shows Promise 62 dasatinib Sprycel ® 62 Zalypsis 62 Trial Issue www.emagazine.com 62 Initiates Phase III 62 rALLy 62 interferon beta 1a infertility 62 Through Glycoscience R 62 Oracea TM 62 NS5B polymerase 62 asthma immunotherapeutic 62 Randomized Phase III 62 non splenectomized 62 CCR9 antagonist 62 Nicotine Vaccine 62 aMCI precursor 62 oral ridaforolimus 62 TELINTRA R 62 Investigational Oral 62 relapsed ALL 62 CRMD# 62 TACI Ig 62 oncolytic virus therapies 62 IMPACT DCM trial 62 IMiDs ® 62 Testosterone MDTS R 62 structure infections ABSSSI 62 zileuton injection 62 PNP inhibitor 62 Phase IIb randomized 62 HGS ETR1 mapatumumab 62 mecarbil 61 CYP#A# substrate 61 ANCHOR trial 61 Hematology Molecular Pathology 61 BCG refractory carcinoma 61 Lymphocytic 61 Phase 2b Study 61 Pivotal Phase II 61 Phase 1a clinical 61 Nasdaq ONXX today 61 Nuvelo Announces 61 keloid scarring 61 PRESS BRIEFING #AM 61 SinuNase TM 61 Dr. Gabriel Lasala 61 Deforolimus 61 REVIVE Diabetes 61 candidates Azedra TM 61 phase IIa 61 albiglutide 61 PMX # heptagonist 61 Dose Ranging Study 61 First Patient Dosed 61 cMET 61 multicenter randomized Phase 61 Zemplar Capsules 61 Bronchiectasis 61 bavituximab monotherapy trial 61 sunitinib Sutent ® 61 biliary tract cancer 61 prospective multicentre 61 somatostatin analog 61 Malignant Glioma 61 PEGylated docetaxel 61 prokinetic agent 61 GRNOPC1 contains 61 Fludara ® 61 Spectrum Pharmaceuticals Announces 61 albiglutide currently 61 novel antimitotic agent 61 Albuferon albinterferon alfa 2b 61 Initiate Phase 61 Val HeFT 61 steroid refractory 61 Immunomedics Announces 61 Peginterferon alfa 2b 61 tumors GIST 61 imetelstat GRN#L 61 blood serum biomarkers 61 Rigel R# 61 STOP SHOPPING FOR 61 #:#-#,# CrossRef Medline [002] 61 Silodosin 61 Evoltra ® 61 Inc. NASDAQ SNUS 61 malignant mesothelioma Alfacell 61 Clostridium difficile Infection 61 vitamin B# folic acid 61 Androxal TM 61 bile duct tumor 61 worsening thrombocytopenia 61 humanised monoclonal antibody 61 Tramiprosate ALZHEMED TM 61 Romiplostim 61 Randomized Study 61 Anturol TM 61 Naive Patients 61 Completes Enrollment 61 Seliciclib 61 PROSTVAC ® 61 Castration Resistant Prostate Cancer 61 GAMMAGARD 61 phase Ib 61 Elagolix 61 landmark ATHENA 61 AFTER FATAL 61 randomized controlled Phase 61 Phase IIb Trial 61 virus HCV protease inhibitor 61 J Am Coll 61 Atypical Hemolytic Uremic Syndrome 61 CINQUIL 61 Adjuvant Treatment 61 metastatic androgen independent 61 Nasdaq IDRA today 61 initiated Phase Ib 61 pan histone deacetylase 61 Metastatic Melanoma 61 Phase III Clinical Trial 61 multicenter phase 61 CIMZIA TM certolizumab pegol 61 Ragweed Allergy 61 GVAX R 61 Soft Tissue Sarcoma 61 renal failure interstitial lung 61 follicular Non Hodgkin 61 Cloretazine 61 carcinoma mCRC 61 immunotherapeutic approaches 61 CBLC# 61 pivotal bioequivalence 61 Fulvestrant 61 Panzem R 61 K ras mutations 61 NPC 1C 61 Double Blind Placebo 61 CTAP# Capsules 61 metaglidasen 61 OAB overactive bladder 61 IMPACT DCM clinical 61 Perifosine KRX 61 Phase III psoriasis 61 includes TOLAMBA TM 61 dose escalation phase 61 vaginal candidiasis 61 previously untreated follicular 61 EOquin TM phase 61 Plaque Psoriasis 61 Get PCMag.com s 61 OvaRex ® MAb 61 Crit Rev 61 Bosutinib 61 R roscovitine 61 PRIMO CABG2 61 CYP#A# CYP#D# 61 forodesine 61 alfa 2a 61 elotuzumab 61 TTR amyloidosis 61 novel emulsion formulation 61 Myelodysplastic Syndrome MDS 61 Acute myelogenous leukemia 61 NO# [002] 61 midstage clinical 61 DOI #.#/cncr.# 61 castration resistant hormone refractory 61 Glioblastoma Multiforme 61 AVI BioPharma Announces 61 Phase IIIb clinical 61 acute peptic ulcer 61 recurrent metastatic 61 Preclinical Efficacy 61 Brentuximab Vedotin SGN 61 CML CP 61 Previously Treated 61 targeting miR 61 Randomized Controlled Trials 61 Quinamed 61 Forodesine HCl 61 Initiates Phase 2b 61 rheumatoid arthritis osteoarthritis ankylosing 61 read Palintologist 61 Shows Promising 61 acyclovir Lauriad R 61 Therapeutic Vaccine 61 Custirsen 61 Amgen Neulasta R 61 IMA# 61 gastrin analogue TT 61 Ozarelix 61 Gentamicin Surgical Implant 61 Antitumor Activity 61 Fovea Pharmaceuticals subsidiary 61 Antigen Specific 61 ALS #-# 61 Phase 1b Clinical Trial 61 R#/MEM # 61 HCV SPRINT 61 Salix Pharmaceuticals Announces 61 Bezielle 61 AA Amyloidosis 61 Pooled Analysis 61 Shows Efficacy 61 decompensated liver disease 61 Nephrol Dial Transplant 61 Colorectal Cancer CRC 61 huN# DM1 61 TKB# 61 non porcine pancreatic 61 metastatic colorectal carcinoma 61 SYMMETRY trial 61 GVAX Pancreas Vaccine 61 Proc Am Soc 61 Commences Phase 61 erlotinib Tarceva ® 61 pentadentate logo R 61 prednisone prednisolone plus 61 GOUT 61 CRLX# 61 CCX# B 61 OMP #R# 61 By EURSOC Two 61 humanized interleukin 6 61 IL# PE#QQR 61 benign prostatic hyperplasia enlarged 61 Thiarabine 61 RAS MAPK pathway 61 Refractory Hodgkin Lymphoma 61 oral dual endothelin 61 Vidaza ® 61 Nasdaq AEGR 61 TBC# 61 Presents Preclinical Data 61 Ph + acute lymphoblastic 61 Drug Candidate 61 azilsartan medoxomil 61 MULLIGAN FAMILY FUN CENTER 61 NDA Submission 61 primary humoral immunodeficiency 61 dual endothelin receptor antagonist 61 neovascular form 61 TRAIL receptor antibody mapatumumab 61 chronic myeloid 61 leukemia AML 61 intravesical infusion therapy 61 By ERIC HJERSTEDT 61 BENLYSTA TM 61 bevirimat Study 61 CEQ# 61 Philadelphia Chromosome Positive 61 DIRECT Trial 60 NSABP C 60 Dose Ranging 60 refractory colorectal cancer 60 LAB CGRP 60 PDX pralatrexate 60 Phase #/#a trial 60 trial evaluating PRX# 60 Amigal TM 60 TEC #OL 60 Randomized Double Blind Placebo 60 Initiate Phase II 60 AEG# 60 angiotensin analog 60 Sergei Fedorov Shaone Morrisonn 60 Delcath Phase III 60 TransVax TM 60 Inc. Nasdaq ALSE 60 unresectable recurrent 60 IN PATIENTS WITH 60 By LEO SHANE 60 eye socket ruptured 60 Cutaneous T 60 anaphylactic reactions bronchospasm 60 Systemic Sclerosis 60 cladribine Cladribine Tablets 60 oral deforolimus 60 Systemic lupus erythematosus SLE 60 AVERROES 60 mason@knews.com 60 SinuNase ™ 60 null responder HCV 60 Novolimus 60 TEMSO 60 Active Ulcerative Colitis 60 immunocompetent adults 60 alpha#beta# integrin 60 Phase 2a Trial 60 J Antimicrob Chemother 60 PDE# inhibitors 60 MEND CABG 60 ADVANCE PD 60 Clinical Efficacy 60 OPT CHF 60 accompanying electrolyte abnormalities 60 coronary stent merged 60 FASEB J. 60 Am J Obstet 60 Confirms Efficacy 60 MAGE A3 ASCI 60 Projected Release Date 60 Phase III AFFIRM 60 RhuDex TM 60 eritoran 60 DMD DMSc 60 Topline Results 60 Ann Oncol 60 MVA MUC1 IL2 60 basal cell carcinoma squamous 60 Medullary Thyroid Cancer 60 Phase III Trial 60 granted Ortec 60 Temsirolimus 60 cancer indications bafetinib 60 cisplatin gemcitabine 60 Neovascular AMD 60 Levels Linked 60 Assistant Dan Dakich 60 Desvenlafaxine Succinate 60 Anthracycline 60 Amgen Neulasta ® 60 known dihydropyrimidine dehydrogenase 60 TO AVOID PREGNANCY WHILE 60 assessing T DM1 60 CDK cyclin dependent 60 gastrointestinal stromal tumor GIST 60 oral Janus kinase 60 chronic thromboembolic pulmonary 60 chronic idiopathic thrombocytopenic purpura 60 TNFerade ™ 60 FDA APPROVES 60 ALVESCO R 60 Gynecologic Oncology Group 60 Xcytrin R 60 LVL MDF plywood 60 RECORD1 60 4 PDE4 enzyme 60 NSABP B 60 recurrent glioma 60 Carlos Checa ESP HANNspree 60 evaluating CK # 60 Menopausal hormone therapy 60 orally administered inhibitor 60 castrate resistant prostate cancer 60 Newly Diagnosed Patients 60 Pagoclone 60 discontinued Viread 60 NASDAQ AVNR 60 registrational trial 60 multicenter placebo controlled 60 irinotecan cisplatin 60 EURONEXT SAN 60 Therapeutic Efficacy 60 AirBoss Announces 60 elderly myelodysplastic syndromes 60 interferon gamma 1b 60 metastatic gastric 60 novel chimeric natriuretic 60 DNA methyltransferase inhibitors 60 toenail onychomycosis 60 LibiGel ® 60 tizanidine hydrochloride short 60 WILL BE ISSUED 60 MEK Inhibitor 60 Emily Blunt shimmered 60 Alzheimer disease cognitive impairment 60 Phase III placebo controlled 60 BR.# 60 pediatric acute lymphoblastic 60 TM pralatrexate injection 60 membranous nephritis 60 hydrochloric acid nitric acid 60 confirmatory pivotal 60 Pharmacodynamic 60 Salima Mabry son 60 Diabetic Macular Edema 60 EDEMA3 60 Therapy RecoveryRx TM 60 SPL# Gel vaginal microbicide 60 ALSYMPCA 60 RIO Diabetes 60 Larry Ellberger 60 multicenter randomized placebo controlled 60 TELINTRA 60 damage cirrhosis liver 60 Cerebril TM 60 Am J Clin 60 data management Clintrial 60 rumpled dresser 60 ViaDerm hPTH #-# 60 BY ADRIAN NEMES 60 CA BUSINESS 60 PRIMO CABG 60 severe oral mucositis 60 ACCEDE 60 evaluate ZFP Therapeutic 60 treatment naive genotype 60 Auxilium anticipates 60 lymphoma multiple myeloma 60 testing huN# DM1 60 Mylan Receives Approval 60 huC# DM4 60 telomerase inhibitor drug 60 Huggins Cams Time 60 metastatic hormone refractory 60 Certolizumab pegol 60 Multicenter Randomized Double 60 clinical trials SGN 60 p# biomarker 60 TOFUTTI products 60 Therapeutic Competitors companiesandmarkets.com adEgemonye 60 octreotide implant 60 nasal calcitonin product 60 Vascular Disrupting Agent 60 stage IIIb IV 60 OYO Geospace Reports 60 TLK# 60 ACTEMRA TM 60 Shows Statistically Significant 60 Arch Surg 60 Cholesterol Levels SPARCL 60 evaluating T DM1 60 Refractory Angina 60 MBRX 60 adecatumumab MT# 60 Perforomist TM formoterol fumarate 60 metastatic GIST 60 Alvine Pharmaceuticals 60 Zenvia ™ 60 IIa trial 60 Jodi Picoult Pocket FP 60 www.pranabio.com 60 Clot Busting 60 RiT Technologies Reports 60 Patients Treated With 60 Subgroup Analysis 60 cardiac myosin activator omecamtiv 60 class mGluR5 inhibitor 60 Inflammatory Arthritis 60 Acute Myelogenous Leukemia AML 60 myelogenous leukemia 60 evaluating carfilzomib 60 nasal decolonization 60 Archexin 60 Newly Diagnosed Breast Cancer 60 successfully commercialize Iluvien 60 multicenter Phase III 60 Sprycel dasatinib 60 idiopathic thrombocytopenic purpura 60 ThermoDox R 60 thalidomide Thalomid 60 vapreotide acetate 60 ARE PUTTING 60 VOID IN 60 Hepatocellular Carcinoma HCC 60 TASKi2 60 Ophena TM 60 Pruvel TM 60 Trial Evaluating 60 Tumor Response 60 Preclinical Models 60 metastatic colorectal 60 Picoplatin Efficacy After 60 RTP #i 60 MGN# 60 Fabry Disease 60 RSD# oral 60 PSMA ADC 60 valopicitabine NM# 60 methylnaltrexone bromide 60 Improves Outcomes 60 CAPACITY trials 60 J Am Acad 60 agents Tabun Sarin 60 relapsed refractory AML 60 TESTIMONY FROM 60 PROGRAM LISTINGS FOR 60 including lacerations puncture 60 Late Breaker 60 mertansine 60 ovarian endometrial 60 Tesmilifene 60 IMiDs R 60 oral sapacitabine 60 Anticancer Drugs 60 itraconazole Sporanox 60 Phase Ib clinical trials 60 LUX Lung 60 Aryplase 60 GLOBE NEWSWIRE Threshold Pharmaceuticals 60 NCCTG N# 60 Invasive pneumococcal disease 60 EMPOWER TM 60 completely resected 60 MKC# 60 Postdoctoral Position 60 include ColorectAlert TM 60 IV RSD# 60 inflammatory PDE 60 TRANSFORMS 60 GW# [003] 60 multicenter Phase 60 LEAGUE AGAIN 60 Submits NDA 60 GEM OS2 60 6 sulfatase 60 unresectable Stage III 60 CUSTOM III 60 MEND CABG II 60 ISTA Pharmaceuticals Announces 60 Inhaled nitric oxide 60 Tanespimycin 60 Carotid Revascularization Endarterectomy vs. 60 #:#-# Abstract Free [009] 60 folate analogue metabolic 60 HOW LONG WAS 60 Pafuramidine 60 hygienic cleansing 60 Fireworks resounded 60 AFREZZA TM 60 Relapsing Multiple Sclerosis 60 generation URAT1 inhibitor 60 Adjuvant Chemotherapy 60 EXPAREL TM 60 Luteinizing hormone 60 nilotinib Tasigna ® 60 metastatic malignant 60 PRT# 60 phase IIb trial 60 TNF antagonist therapy 59 Hematide ™ 59 unresectable tumors 59 targeted anticancer biopharmaceuticals 59 chronic myocardial ischemia 59 Slows Progression 59 eosinophilic asthma 59 Shortened telomeres 59 Ridaforolimus 59 paclitaxel Taxol R 59 Patient Accrual 59 ORACLE MS 59 Golimumab 59 Sandostatin R 59 Intravenous palifosfamide 59 Vitaxin 59 Phase #/#a 59 Non Alcoholic Steatohepatitis 59 Ambrilia Biopharma Provides 59 Momenta Pharmaceuticals Announces 59 oral prodrug 59 Microplasmin 59 PROTEGE 59 systemic juvenile idiopathic 59 Paclitaxel Carboplatin 59 By PETER LARSEN 59 Treatment Experienced 59 Pruvel ™ prulifloxacin 59 brivanib 59 apricitabine ATC 59 anti PlGF 59 ® decitabine 59 Genasense ® oblimersen 59 NEBIDO VANTAS SUPPRELIN LA 59 Commence Phase 59 Advaxis Phase 59 Denufosol 59 Ann Rheum Dis 59 Renal Cell Carcinoma RCC 59 Chronic Heart Failure 59 Eculizumab 59 Maximum Tolerated Dose MTD 59 Anti VEGF 59 REVIVE TA 59 Nasdaq PCYC 59 Pole sitter Jamie McMurray 59 rheumatoid arthritis inflammatory bowel 59 EGFr humanized monoclonal antibody 59 Remission Maintenance 59 oral rivaroxaban 59 Biomarker Study 59 Complicated Skin 59 NASH Huntington 59 PhotoPoint R 59 ruffle hem black 59 USP Tablets PEPCID 59 TRANSDUR ® 59 gastrointestinal stromal 59 IgG1 monoclonal antibody 59 YONDELIS 59 NPM1 mutations 59 lucinactant 59 Gatherings alternate 59 Aplidin R 59 stage IIIb 59 Alocrest 59 Pertuzumab 59 ANN INTERN MED 59 njobst@dmreg.com 59 See CONTRAINDICATIONS 59 HIV coinfected 59 PROBABLE STARTERS Cavaliers 59 Zoraxel 59 sorafenib tablets 59 Advanced Melanoma 59 By KATHARINE HARMON 59 Folfox 59 Cannabinor 59 FDA Accepts 59 By JENNIFER KOVACS 59 Prodarsan 59 Genasense ® 59 Anti Tumor Activity 59 Hematological 59 Exherin TM 59 RSD# IV 59 Hepatocellular Carcinoma 59 randomized controlled multicenter 59 administering VIVITROL 59 By Georgina Enzer 59 Cloretazine R VNP#M 59 BioNumerik 59 First Patient Enrolled 59 monoclonal antibody IgG1 Mab 59 Sleep Disturbances 59 HGS ETR2 59 Sun.Star Baguio newspaper 59 XL# XL# XL# XL# 59 Predict Response 59 David Rapperport Quest 59 KYLE BUSCH DRIVER 59 introduced NEUGENE 59 receptor tyrosine kinase inhibitor 59 APEX PD 59 de novo kidney transplant 59 Phase 2a Clinical Trial 59 Valero Benicia #.# 59 By TERRANCE HARRIS 59 Phase III Psoriasis 59 ASONEP TM 59 ENDEAVOR IV 59 Sipuleucel T 59 Dermatol 59 By Stefanos Evripidou 59 Grouped Hockey 59 CYP#A# isoenzyme 59 vaccine GMK 59 novel tubulin binding 59 dirucotide MBP# 59 acute mania 59 Treatment Naïve 59 BY STEFANIE WHITE 59 GATTEX TM 59 Blinatumomab 59 commercialize deforolimus 59 acute myelogenous 59 CD#.# DOES NOT ENDORSE 59 Adenoviral 59 Phase IIIb 59 rib cage mangled 59 TAXUS VI 59 Vasogen Announces 59 manufactures minimally invasive 59 trastuzumab emtansine T DM1 59 Anticancer Drug 59 BY DAVID CRIGGER 59 common neurovascular complication 59 ADVEXIN therapy 59 Completes Dosing